摘要:美国食品与药品监督管理局(FDA)批准扩展Xalkorl(Crjzotlnm)的适用范围,将其应用于携带有ROS-1基因突变的晚期(转移性)非小细胞肺癌(NSCLC)的治疗当中。Xalkori是美国食品药品管理局批准的首个,也是唯一一个治疗带有ROS-1基因突变的阳性非小细胞肺癌(NSCLC)的药物。
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
Journal of Hydrodynamics Journal of Huazhong University of Science and Technology The Journal of China Universities of Posts and Telecommunications Journal of Genetics and Genomics Journal of Iron and Steel Research Journal of Systems Science and Complexity World Journal of Gastroenterology Journal of Computer Science and Technology Applied Mathematics:A Journal of Chinese Universities International Journal of Minerals Metallurgy and Materials International Journal of Mining Science and Technology Journal of Systems Science and Systems Engineering